This new class of weight loss drugs are costly - but is there a greater price to ignoring the problem?
If you have read the news, watched cable TV, rode the subway, or been on TikTok in the last six months, you’ve most certainly heard of weight loss drugs like Mounjaro and Ozempic. These “GLP-1” drugs which stand for glucagon-like peptides, have been hailed by celebrities and weight loss influencers as modern medical miracles and as the ultimate solution to our massive obesity epidemic. The message seems to be reaching its audience: one recent survey showed 3 in 10 Americans are interested in trying a GLP-1. (To be technically accurate here, Mounjaro is the first-of-its-kind to activate both the GLP-1 and GIP receptors, which leads to improved blood sugar control.)
It is true that this class of drugs — which are also used to treat type 2 diabetes and other weight-related conditions, versus purely cosmetic weight loss — show promising efficacy, delivering 15% average weight loss at one year with a decent safety profile. Though a list of side-effects is also well documented.
How they work:
`Upcoming Sessions
Live conversations with the people shaping healthcare.
Verifying AI in Medicine: Is Healthcare AI Actually Ready for Deployment?
Is AI ready for real-world clinical care? Dr. Zak Kohane and Protege’s Engy Ziedan debate what it takes to safely trust AI in diagnosis and treatment, from benchmark performance and clinical evidence to whether we’re holding AI to a higher standard than humans.
Why Are Hospitals Hiring Chief AI Officers?
As AI moves from pilots into day-to-day healthcare operations, health systems are having to decide who should actually own the
Where are AI Agents Actually Working in Healthcare, and Why?
While the healthcare industry remains locked in a high-level debate over the theoretical potential of artificial intelligence, a select group of
Top Employers Share What Healthcare Startups Need to Know in 2026
As enterprise health purchasers face volatile medical cost trends and tightening operational margins, the standard vendor pitch of "improved clinical efficiency&
Peptide Therapy: Where Do We Go From Here?
Watch the full webinar Peptide therapies have moved from niche biohacking circles into mainstream medicine, reshaping conversations around weight management, metabolic health,
Not everyone can access the top 1% of physicians. Will AI change that?
Historically, top-tier medical expertise was limited by wealth and geography. As AI reshapes healthcare delivery, a vital question emerges: can it democratize intelligence to give everyone access to the caliber of care typically reserved for the top 1%?
Privacy AI and the Future of HIPAA
Watch the Full Webinar As AI reshapes healthcare and more patient data flows beyond traditional clinical settings, the rules governing privacy, access,
What will AI do for employer healthcare and benefits?
Employer healthcare may be one of the most practical — and overlooked — proving grounds for AI.
Hospitals as the new go-to-market, lessons from the trenches
Watch the Full Webinar Health systems are entering a new frontier, one where innovation isn’t optional, and meaningful change requires creativity,